Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18819435 | MODELS OF TAUOPATHY | August 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18765750 | SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATION | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18673713 | TRANS-SPLICING MOLECULES | May 2024 | June 2025 | Allow | 13 | 0 | 0 | No | No |
| 18441280 | COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERY | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18407780 | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18407815 | Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell | January 2024 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18406159 | SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATION | January 2024 | June 2024 | Allow | 6 | 0 | 0 | No | No |
| 18392181 | Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors | December 2023 | October 2024 | Allow | 10 | 1 | 0 | No | No |
| 18512207 | Aptamers For Personal Health Care Applications | November 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18511108 | DNA Monoclonal Antibodies Targeting Influenza Virus | November 2023 | May 2025 | Allow | 18 | 2 | 0 | No | No |
| 18502516 | MODELS OF TAUOPATHY | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18503125 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | November 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18381238 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | October 2023 | December 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18487429 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | October 2023 | November 2024 | Allow | 13 | 2 | 0 | No | No |
| 18368248 | APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONS | September 2023 | October 2024 | Abandon | 13 | 0 | 1 | No | No |
| 18450033 | VIRAL VECTOR PRODUCTION | August 2023 | February 2025 | Allow | 18 | 1 | 0 | No | No |
| 18448254 | METHODS FOR PRODUCTION OF MSC-DERIVED EXOSOMES | August 2023 | June 2025 | Allow | 22 | 1 | 1 | No | No |
| 18356404 | Methods for Treatment of Alport Syndrome | July 2023 | October 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18345452 | ANGELMAN SYNDROME ANTISENSE TREATMENT | June 2023 | September 2024 | Allow | 14 | 2 | 0 | No | No |
| 18342409 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18205390 | NUCLEOLIN-TARGETING APTAMERS AND METHODS OF USING THE SAME | June 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18316556 | Albumin Production and Cell Proliferation | May 2023 | September 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18315890 | MODULATING APOLIPOPROTEIN (A) EXPRESSION | May 2023 | April 2025 | Allow | 24 | 2 | 0 | No | No |
| 18296912 | SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES | April 2023 | November 2023 | Allow | 7 | 1 | 0 | No | No |
| 18128949 | ANTIDOTE-MEDIATED REVERSAL OF EXTRACELLULAR APTAMER STAINING | March 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18168066 | Screening artificial nucleic acids by particle display | February 2023 | February 2025 | Allow | 24 | 1 | 2 | No | No |
| 18165113 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS | February 2023 | August 2024 | Allow | 18 | 1 | 0 | No | No |
| 18155945 | COMPOSITIONS FOR MODULATING TAU EXPRESSION | January 2023 | March 2024 | Allow | 14 | 1 | 0 | No | No |
| 18080049 | METHOD FOR TREATING CARDIOVASCULAR DISEASE | December 2022 | November 2024 | Abandon | 23 | 2 | 0 | No | No |
| 18055525 | METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS | November 2022 | April 2025 | Allow | 29 | 1 | 1 | No | No |
| 18055212 | ANGLEMAN SYNDROME ANTISENSE TREATMENT | November 2022 | June 2023 | Allow | 7 | 2 | 0 | No | No |
| 18053679 | ANTISENSE NUCLEIC ACIDS | November 2022 | October 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17982469 | C5a Binding Nucleic Acids | November 2022 | August 2024 | Allow | 22 | 0 | 0 | No | No |
| 18051821 | METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS | November 2022 | May 2025 | Allow | 30 | 1 | 1 | No | No |
| 18051487 | AMPHIPHILIC POLYNUCLEOTIDES | October 2022 | December 2023 | Allow | 13 | 0 | 1 | No | No |
| 18045357 | TREATING METASTATIC CANCER AND MODEL SYSTEMS FOR METASTATIC DISEASE | October 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17930364 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA | September 2022 | January 2023 | Allow | 5 | 1 | 0 | No | No |
| 17895007 | ANTICANCER COMPOSITIONS AND METHODS FOR MAKING AND USING THEM | August 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17892686 | COMPOSITIONS AND METHODS FOR IDENTIFYING POLYNUCLEOTIDES OF INTEREST | August 2022 | May 2024 | Allow | 20 | 0 | 1 | No | No |
| 17816059 | MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOF | July 2022 | March 2025 | Allow | 31 | 2 | 1 | No | No |
| 17816084 | Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors | July 2022 | September 2023 | Allow | 14 | 1 | 0 | No | No |
| 17812576 | TRANSLATABLE MOLECULES AND SYNTHESIS THEREOF | July 2022 | November 2023 | Allow | 16 | 1 | 0 | No | No |
| 17861676 | METHOD FOR REDUCING THE EXPRESSION OF NKCC1 IN A SUBJECT | July 2022 | July 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17860141 | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | July 2022 | June 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17852939 | Compounds and Methods for Reducing ATXN3 Expression | June 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17849294 | TWIST SIGNALING INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME | June 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17844877 | Heterologous UTR Sequences for Enhanced mRNA Expression | June 2022 | January 2024 | Allow | 18 | 0 | 1 | No | No |
| 17746387 | METHODS OF INDUCING INSULIN PRODUCTION | May 2022 | April 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17724176 | COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION | April 2022 | July 2022 | Allow | 3 | 0 | 0 | No | No |
| 17716497 | Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same | April 2022 | August 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17714196 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | April 2022 | June 2022 | Allow | 2 | 0 | 0 | No | No |
| 17694482 | CD44 APTAMER | March 2022 | July 2023 | Allow | 16 | 0 | 1 | No | No |
| 17692048 | METHODS AND COMPOSITIONS TO DIRECT BREAKDOWN OF INSULIN MRNA IN BENIGN FASHION | March 2022 | May 2025 | Abandon | 38 | 2 | 1 | No | No |
| 17668504 | INHIBITION OF KMT2D FOR THE TREATMENT OF CANCER | February 2022 | May 2023 | Allow | 15 | 0 | 0 | No | No |
| 17570313 | COMBINATION VECTORS AND METHODS FOR TREATING CANCER | January 2022 | March 2025 | Allow | 38 | 1 | 2 | No | No |
| 17569658 | THERAPEUTIC ALTERATION OF TRANSPLANTABLE TISSUES THROUGH IN SITU OR EX VIVO EXPOSURE TO RNA INTERFERENCE MOLECULES | January 2022 | May 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17645895 | APPLICATION OF AGENT IN PREPARATION OF MEDICINE FOR TREATING/INHIBITING PSORIASIS | December 2021 | April 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17531913 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17531921 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17531885 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | March 2022 | Allow | 3 | 1 | 0 | No | No |
| 17531900 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | March 2022 | Allow | 3 | 1 | 0 | No | No |
| 17531919 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17531888 | ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2021 | March 2022 | Allow | 3 | 1 | 0 | No | No |
| 17523456 | ANGELMAN SYNDROME ANTISENSE TREATMENT | November 2021 | April 2023 | Allow | 17 | 1 | 0 | No | No |
| 17610000 | DIMERIC CPG OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSES | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17517891 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | November 2021 | September 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17607616 | PD-L1 antisense oligonucleotides for use in tumor treatment | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17604707 | MOLECULAR MARKER DETECTION AND REGULATING METHODS IN DE-SERVITIZATION STATE OF CELLS | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17602740 | NUCLEIC ACID NANOSTRUCTURES CROSSLINKED WITH OLIGOLYSINE | October 2021 | December 2024 | Allow | 38 | 0 | 0 | No | No |
| 17493112 | METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION | October 2021 | December 2023 | Allow | 26 | 1 | 0 | No | No |
| 17490611 | ADENO-ASSOCIATED VIRAL VECTORS USEFUL IN TREATMENT OF SPINAL MUSCULAR ATROPY | September 2021 | October 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17486488 | HIGH-EFFICIENCY RECONSTITUTION OF RNA MOLECULES | September 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17484386 | COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION | September 2021 | July 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17442301 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERS | September 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17475795 | OLIGONUCLEOTIDES TO TREAT EYE DISEASE | September 2021 | November 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17473209 | ARC-BASED CAPSIDS AND USES THEREOF | September 2021 | July 2022 | Abandon | 10 | 0 | 1 | No | No |
| 17469530 | AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMAS | September 2021 | June 2024 | Allow | 33 | 1 | 0 | No | No |
| 17436721 | microRNA Expression Promoting Agent and Food or Beverage for Promoting Expression of microRNA | September 2021 | February 2025 | Allow | 41 | 2 | 0 | No | No |
| 17461797 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | August 2021 | May 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17434317 | INFLAMMASOME-TARGETED RNA INTERFERENCE APPROACH TO TREATING KIDNEY INJURY AND DISEASE | August 2021 | January 2025 | Allow | 41 | 1 | 1 | No | No |
| 17411932 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA | August 2021 | July 2022 | Allow | 11 | 1 | 1 | No | No |
| 17411313 | MODULATING THE CELLULAR STRESS RESPONSE | August 2021 | July 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17411265 | SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER | August 2021 | June 2023 | Allow | 22 | 1 | 0 | No | No |
| 17408920 | Compositions and Methods for Modulating MECP2 Expression | August 2021 | March 2025 | Allow | 42 | 1 | 2 | No | No |
| 17432720 | ANTIBODIES AND ENONOMERS | August 2021 | June 2025 | Allow | 46 | 3 | 1 | No | No |
| 17402459 | DUAL TARGETING siRNA AGENTS | August 2021 | September 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17310579 | METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1 | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17396760 | COMBINATION OF VACCINATION AND OX40 AGONISTS | August 2021 | August 2024 | Allow | 36 | 1 | 1 | No | No |
| 17375877 | ANTISENSE NUCLEIC ACIDS | July 2021 | January 2022 | Abandon | 6 | 1 | 0 | Yes | No |
| 17369783 | MRNA THERAPY FOR POMPE DISEASE | July 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17367096 | MODULATION OF PREKALLIKREIN (PKK) EXPRESSION | July 2021 | July 2023 | Allow | 24 | 0 | 1 | No | No |
| 17366796 | Methods for Treatment of Alport Syndrome | July 2021 | October 2023 | Abandon | 28 | 2 | 0 | No | No |
| 17366835 | LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORS | July 2021 | March 2023 | Allow | 20 | 1 | 0 | No | No |
| 17359905 | Compositions and Methods for Treating Cancer | June 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17356828 | Aptamers For Personal Health Care Applications | June 2021 | November 2023 | Allow | 28 | 1 | 1 | No | No |
| 17353559 | INSECT CONTROL STRATEGIES UTILITIZING PHEROMONES AND RNAI | June 2021 | August 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17312326 | NUCLEIC ACID BIOMARKERS FOR PLACENTAL DYSFUNCTION | June 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17311970 | METHODS OF DETECTING, PREVENTING, REVERSING, AND TREATING NEUROLOGICAL DISEASES | June 2021 | July 2025 | Allow | 49 | 1 | 2 | No | No |
| 17337762 | MODULATION OF LNC05 EXPRESSION | June 2021 | May 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17298803 | SHORT DNA APTAMERS AND METHODS FOR PROMOTING REMYELINATION | June 2021 | February 2024 | Allow | 33 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCGARRY, SEAN.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCGARRY, SEAN works in Art Unit 1635 and has examined 959 patent applications in our dataset. With an allowance rate of 61.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner MCGARRY, SEAN's allowance rate of 61.4% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCGARRY, SEAN receive 1.22 office actions before reaching final disposition. This places the examiner in the 21% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCGARRY, SEAN is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +22.5% benefit to allowance rate for applications examined by MCGARRY, SEAN. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.9% of applications are subsequently allowed. This success rate is in the 54% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 60.3% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 90.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 62.9% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.1% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.8% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.